Brentuximab vedotin and ICE Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Brentuximab vedotin and ICE Therapy, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD30 +, HER2-negative Hodgkin Lymphoma Brentuximab Vedotin, Carboplatin, Etoposide, Ifosfamide